Candriam S.C.A. Bicycle Therapeutics PLC Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCYC
# of Institutions
112Shares Held
41.2MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$212 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$80.1 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$52.8 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$50.9 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$44.2 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $670M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...